Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

被引：0
|
作者：
U Platzbecker
F Braulke
A Kündgen
K Götze
G Bug
C Schönefeldt
K Shirneshan
C Röllig
M Bornhäuser
R Naumann
J Neesen
A Giagounidis
W-K Hofmann
G Ehninger
U Germing
D Haase
M Wermke
机构：
[1] Medical Clinic and Polyclinic I,Department of Hematology and Oncology
[2] University Hospital,Department of Hematology and Oncology
[3] Technical University Dresden,undefined
[4] University Hospital,undefined
[5] University Göttingen,undefined
[6] University Hospital,undefined
[7] Heinrich Heine University Düsseldorf,undefined
[8] Medical Clinic,undefined
[9] University Hospital,undefined
[10] Technical University Munich,undefined
[11] Clinic of Hematology and Oncology,undefined
[12] J.W. Goethe University Hospital,undefined
[13] Stiftungsklinikum Mittelrhein,undefined
[14] Institute of Medical Genetics,undefined
[15] Medical University Vienna,undefined
[16] St Johannes Hospital,undefined
[17] Clinic of Hematology and Oncology,undefined
[18] Hospital of the Ruprecht Karls University,undefined
来源：
Leukemia | 2013年 / 27卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1403 / 1407
页数：4
相关论文
共 50 条
  • [31] A PHASE II STUDY EXPLORING THE FEASIBILITY OF AZACITIDINE AND LENALIDOMIDE USE (COMBINATION vs SEQUENTIAL TREATMENT) FOR HIGHER-RISK MYELODYSPLASTIC SYNDROMES (IPSS RISK: HIGH OR INT-2)
    Finelli, C.
    Clissa, C.
    Follo, M. Y.
    Stanzani, M.
    Avanzini, P.
    Bosi, C.
    Castagnari, B.
    Candoni, A.
    Crugnola, M.
    Giannini, M. B.
    Gobbi, M.
    Leonardi, G.
    Rigolin, G. M.
    Russo, D.
    Tosi, P.
    Visani, G.
    Farnedi, A.
    Cavo, M.
    HAEMATOLOGICA, 2014, 99 : 347 - 347
  • [32] A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias
    Jain, Nitin
    Cortes, Jorge E.
    Estrov, Zeev
    Borthakur, Gautam
    Dong, Xiao Q.
    Kumar, Veeral J.
    Kantarjian, Hagop M.
    BLOOD, 2013, 122 (21)
  • [33] A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure
    Thepot, Sylvain
    Boehrer, Simone
    Seegers, Valerie
    Prebet, Thomas
    Beyne-Rauzy, Odile
    Wattel, Eric
    Delaunay, Jacques
    Raffoux, Emmanuel
    Hunault, Mathilde
    Jourdan, Eric
    Chermat, Fatiha
    Sebert, Marie
    Kroemer, Guido
    Fenaux, Pierre
    Ades, Lionel
    LEUKEMIA RESEARCH, 2014, 38 (12) : 1430 - 1434
  • [34] Response to azacitidine is independent of TP53 mutations in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia
    Mueller-Thomas, C.
    Rudelius, M.
    Wolf, P.
    Schanz, J.
    Schmidt, B.
    Platzbecker, U.
    Germing, U.
    Peschel, C.
    Goetze, K.
    LEUKEMIA RESEARCH, 2013, 37 : S73 - S74
  • [35] Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia
    Mueller-Thomas, Catharina
    Rudelius, Martina
    Rondak, Ina-Christine
    Haferlach, Torsten
    Schanz, Julie
    Huberle, Christina
    Schmidt, Burkhard
    Blaser, Rainer
    Kremer, Marcus
    Peschel, Christian
    Germing, Ulrich
    Platzbecker, Uwe
    Goetze, Katharina
    HAEMATOLOGICA, 2014, 99 (10) : E179 - E181
  • [36] The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)
    Seymour, John F.
    Silverman, Lewis R.
    Doehner, Hartmut
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Minden, Mark D.
    Stone, Richard M.
    Lucy, Lela M.
    Songer, Stephen
    Dougherty, Donna
    Hinkle, Randy
    Gambini, Dominique
    Beach, C. L.
    Dombret, Herve
    BLOOD, 2015, 126 (23)
  • [37] Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    O'Keefe, Christine
    List, Alan F.
    Paulic, Katarina
    Afable, Manuel, II
    Englehaupt, Ricki
    Maciejewski, Jaroslaw P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (01) : 102 - 103
  • [38] Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
    Garcia-Manero, Guillermo
    Gore, Steven D.
    Cogle, Christopher
    Ward, Renee
    Shi, Tao
    MacBeth, Kyle J.
    Laille, Eric
    Giordano, Heidi
    Sakoian, Sarah
    Jabbour, Elias
    Kantarjian, Hagop
    Skikne, Barry
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : 2521 - 2527
  • [39] Sequential azacitidine and lenalidomide in elderly acute myeloid leukemia: completed results of the phase I study
    Pollyea, D. A.
    Kohrt, H. E.
    Gallegos, L.
    Zhang, B.
    Figueroa, M.
    Melnick, A.
    Berube, C.
    Coutre, S. E.
    Gotlib, J. R.
    Zehnder, J. L.
    Liedtke, M.
    Mitchell, B. S.
    Medeiros, B. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML)
    Pollyea, Daniel A.
    Kohrt, Holbrook E.
    Gallegos, Leonel
    Berube, Caroline
    Coutre, Steven
    Gotlib, Jason
    Liedtke, Michaela
    Mitchell, Beverly S.
    Medeiros, Bruno C.
    BLOOD, 2010, 116 (21) : 1347 - 1347
12345